U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C33H40N2O9.ClH
Molecular Weight 645.1408
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of RESERPINE HYDROCHLORIDE

SMILES

COc1ccc2c3CCN4C[C@@]5([H])C[C@]([H])([C@@]([H])([C@]([H])([C@@]5([H])C[C@]4([H])c3[nH]c2c1)C(=O)OC)OC)OC(=O)c6cc(c(c(c6)OC)OC)OC.Cl

InChI

InChIKey=ZYWIWGUMKCZKOO-BQTSRIDJSA-N
InChI=1S/C33H40N2O9.ClH/c1-38-19-7-8-20-21-9-10-35-16-18-13-27(44-32(36)17-11-25(39-2)30(41-4)26(12-17)40-3)31(42-5)28(33(37)43-6)22(18)15-24(35)29(21)34-23(20)14-19;/h7-8,11-12,14,18,22,24,27-28,31,34H,9-10,13,15-16H2,1-6H3;1H/t18-,22+,24-,27-,28+,31+;/m1./s1

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.4609
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C33H40N2O9
Molecular Weight 608.68
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 6 / 6
E/Z Centers 0
Optical Activity UNSPECIFIED

Reserpine is an alkaloid, isolated from the Rauwolfia serpentina plant and developed by Ciba pharma. Reserpine was approved by FDA for the treatment of hypertension and psychotic disorders. The drug exerts its effect by blocking two vesicular monoamine transporters, VMAT1 and VMAT2. The blockade results in vesicles that lose their ability to store neurotransmitter molecules. Neurotransmitters, thus retained in cytosol, are then neutralized by MAO.

Originator

Curator's Comment:: Later Ciba-Geigy and now Novartis.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
160.0 nM [IC50]
350.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
RESERPINE

Approved Use

Mild essential hypertension; also useful as adjunctive therapy with other antihypertensive agents in the more severe forms of hypertension; relief of symptoms in agitated psychotic states (e.g., schizophrenia), primarily in those individuals unable to tolerate phenothiazine derivatives or in those who also require antihypertensive medication.

Launch Date

-4.66300797E11
Palliative
RESERPINE

Approved Use

Mild essential hypertension; also useful as adjunctive therapy with other antihypertensive agents in the more severe forms of hypertension; relief of symptoms in agitated psychotic states (e.g., schizophrenia), primarily in those individuals unable to tolerate phenothiazine derivatives or in those who also require antihypertensive medication.

Launch Date

-4.66300797E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.2 ng/mL
2.5 mg single, oral
dose: 2.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RESERPINE plasma
Equus caballus
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
4.8 ng × h/mL
2.5 mg single, oral
dose: 2.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RESERPINE plasma
Equus caballus
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
23.6 h
2.5 mg single, oral
dose: 2.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RESERPINE plasma
Equus caballus
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
Doses

Doses

DosePopulationAdverse events​
0.25 mg 2 times / day multiple, oral
Dose: 0.25 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.25 mg, 2 times / day
Sources:
unhealthy, 41.2 years
n = 60
Health Status: unhealthy
Condition: cocaine dependence
Age Group: 41.2 years
Sex: M+F
Population Size: 60
Sources:
Disc. AE: Drowsiness, Light headedness...
AEs leading to
discontinuation/dose reduction:
Drowsiness (1 patient)
Light headedness (light, 1 patient)
Sources:
0.25 mg 2 times / day multiple, oral
Dose: 0.25 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.25 mg, 2 times / day
Sources:
unhealthy, 41.2 years
n = 60
Health Status: unhealthy
Condition: cocaine dependence
Age Group: 41.2 years
Sex: M+F
Population Size: 60
Sources:
Disc. AE: Upper abdominal pain, Postural hypotension...
AEs leading to
discontinuation/dose reduction:
Upper abdominal pain (1 patient)
Postural hypotension (1 patient)
Electrocardiogram abnormal (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Drowsiness 1 patient
Disc. AE
0.25 mg 2 times / day multiple, oral
Dose: 0.25 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.25 mg, 2 times / day
Sources:
unhealthy, 41.2 years
n = 60
Health Status: unhealthy
Condition: cocaine dependence
Age Group: 41.2 years
Sex: M+F
Population Size: 60
Sources:
Light headedness light, 1 patient
Disc. AE
0.25 mg 2 times / day multiple, oral
Dose: 0.25 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.25 mg, 2 times / day
Sources:
unhealthy, 41.2 years
n = 60
Health Status: unhealthy
Condition: cocaine dependence
Age Group: 41.2 years
Sex: M+F
Population Size: 60
Sources:
Electrocardiogram abnormal 1 patient
Disc. AE
0.25 mg 2 times / day multiple, oral
Dose: 0.25 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.25 mg, 2 times / day
Sources:
unhealthy, 41.2 years
n = 60
Health Status: unhealthy
Condition: cocaine dependence
Age Group: 41.2 years
Sex: M+F
Population Size: 60
Sources:
Postural hypotension 1 patient
Disc. AE
0.25 mg 2 times / day multiple, oral
Dose: 0.25 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.25 mg, 2 times / day
Sources:
unhealthy, 41.2 years
n = 60
Health Status: unhealthy
Condition: cocaine dependence
Age Group: 41.2 years
Sex: M+F
Population Size: 60
Sources:
Upper abdominal pain 1 patient
Disc. AE
0.25 mg 2 times / day multiple, oral
Dose: 0.25 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.25 mg, 2 times / day
Sources:
unhealthy, 41.2 years
n = 60
Health Status: unhealthy
Condition: cocaine dependence
Age Group: 41.2 years
Sex: M+F
Population Size: 60
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [Activation >3.9811 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no
no
unlikely [Inhibition 20 uM]
weak [IC50 133 uM]
weak [IC50 133 uM]
weak [IC50 58 uM]
yes [IC50 2.8 uM]
yes [IC50 20.4 uM]
yes [IC50 26.3 uM]
yes [IC50 <0.03 uM]
yes [IC50 <0.2 uM]
yes [Inhibition 20 uM]
yes [Inhibition 20 uM]
yes [Ki 1.38 uM]
yes [Ki 295 uM]
yes
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
The effect of 5-hydroxytrytamine synthesis inhibitors on neuroleptic-induced catalepsy in rats.
1975
Pharmacological analysis of a new anorexic substance: 5-hydroxy-5(4'-chlorophenyl)-2, 3-dihydro-5H-imidazo-(2, 1-a) isoindole (Mazindol).
1975 Apr
Effects of aminergic drugs and glutamic acid on audiogenic seizures induced by early exposure to ethanol.
1975 Mar
[Behavior pharmacology of maprotiline, a new antidepressant].
1975 Nov
Transient global amnesia associated with cardiac arrhythmia and digitalis intoxication.
1975 Sep-Oct
[Characterization and recognition key components in Astragalus membranaceus].
2001 Jul
[Determination of intestinal trefoil factor in burned rats by reversed-phase high performance liquid chromatography].
2001 Jul
[Study of diphacinone in biological samples by high performance liquid chromatography/diode array detector].
2001 May
[Determination of acyclovir in mouse plasma and tissues by reversed-phase high performance liquid chromatography].
2001 Nov
[Determination of nitidine in different parts of Zanthoxylum nitidum].
2001 Sep
Studies on the cardiotoxicity of noradrenaline in isolated rabbit hearts.
2002
Identification of mammary carcinogens in rodent bioassays.
2002
Behavioral effects of MK-801 on reserpine-treated mice.
2002 Apr
Heterologous expression of a Rauvolfia cDNA encoding strictosidine glucosidase, a biosynthetic key to over 2000 monoterpenoid indole alkaloids.
2002 Apr
Augmentation of immune cell activity against tumor cells by Rauwolfia radix.
2002 Aug
High-performance liquid chromatographic, capillary electrophoretic and capillary electrophoretic-electrospray ionisation mass spectrometric analysis of selected alkaloid groups.
2002 Aug 16
[Determination of ofloxacin in human fallopian tube, uterus and serum by high performance liquid chromatography].
2002 Feb
Temperature effect on peak width and column efficiency in subcritical water chromatography.
2002 Feb
Direct-injection HPLC assay for the determination of a new carbapenem antibiotic in human plasma and urine.
2002 Feb 1
Simultaneous determination of cloricromene and its active metabolite in rabbit aqueous humor by high-performance liquid chromatography.
2002 Feb 5
Development and validation of a reversed-phase high-performance liquid chromatographic method for the determination of ethyl-3-(N-n-butyl-N-acetyl)aminopropionate in an insect repellent semi-solid formulation.
2002 Feb 8
Nitecapone and selegiline as effective adjuncts to L-DOPA in reserpine-induced catatonia in mice.
2002 Jan-Feb
Determination of L-sesamin and L-asarinin in Zanthoxylum(Roxb.) DC. by high performance liquid chromatography.
2002 Jul
Increase of free cysteine and citric acid in plant cells exposed to cobalt ions.
2002 Jul
Determination of terbutaline sulfate and its degradation products in pharmaceutical formulations using LC.
2002 Jul 31
Validated HPLC method for determination of sennosides A and B in senna tablets.
2002 Jul 31
Rapid high-performance liquid chromatographic assay of dorzolamide in rabbit aqueous humor.
2002 Jun
Determination of ethylenediamine tetraacetic acid in injection forms by ion-pair chromatography.
2002 Jun 15
Simultaneous determination of N-oxides and free bases of pyrrolizidine alkaloids by cation-exchange solid-phase extraction and ion-pair high-performance liquid chromatography.
2002 Mar 8
[The effect of shourong compound formula on levels of dopamine and its metabolites in brain of Parkinson's disease mice induced by reserpine].
2002 May
[Determination of aspirin and free salicylic acid in lysinipirine injection by high performance liquid chromatography].
2002 May
LC-MS/MS determination of a farnesyl transferase inhibitor in human plasma and urine.
2002 Nov 7
Determination of undecylenic and sorbic acids in cosmetic preparations by high performance liquid chromatography with electrochemical detection.
2002 Nov 7
A modified HPLC method for the determination of ochratoxin A by fluorescence detection.
2002 Oct
Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.
2002 Oct
Development and substantiation of a liquid chromatographic method for monitoring organic reactions involved in synthesis of 4-methoxyphenylacetic acid.
2002 Oct 4
Osteology and skeletal development of Apalone spinifera (Reptilia: Testudines: Trionychidae).
2003 Apr
Expression of heart K+ channels in adrenalectomized and catecholamine-depleted reserpine-treated rats.
2003 Feb
Determination of peptides and amino acids from wool and beer with sensitive fluorescent reagent 2-(9-carbazole)-ethyl chloroformate by reverse phase high-performance liquid chromotography and liquid chromotography mass spectrometry.
2003 Feb 1
Antitumour 2-(4-aminophenyl)benzothiazoles generate DNA adducts in sensitive tumour cells in vitro and in vivo.
2003 Feb 10
DNA damage and cell cycle arrest induced by 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203, NSC 703786) is attenuated in aryl hydrocarbon receptor deficient MCF-7 cells.
2003 Feb 24
Optimization and validation of conventional and micellar LC methods for the analysis of methyltestosterone in sugar-coated pills.
2003 Feb 5
Analysis of selected withanolides in plant extract by capillary electrochromatography and microemulsion electrokinetic chromatography.
2003 Jan
Growth-inhibitory effects of the chemopreventive agent indole-3-carbinol are increased in combination with the polyamine putrescine in the SW480 colon tumour cell line.
2003 Jan 14
Analysis of flecainide and two metabolites in biological specimens by HPLC: application to a fatal intoxication.
2003 Jan-Feb
Quercetin potentiates L-Dopa reversal of drug-induced catalepsy in rats: possible COMT/MAO inhibition.
2003 Jun
Rat stomach ECL cells: mode of activation of histidine decarboxylase.
2003 Jun 15
Studies on the long-term thermal stability of stationary phases in subcritical water chromatography.
2003 Mar 7
Assessment of a controlled release hydrophilic matrix formulation for metoclopramide HCl.
2003 May
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.
2003 May 21
Patents

Sample Use Guides

Hypertension: In the average patient not receiving other antihypertensive agents, the usual initial dosage is 0.5 mg daily for 1 or 2 weeks. For maintenance, reduce to 0.1-0.25 mg daily. Psychiatric Disorders: the usual initial dosage is 0.5 mg daily, but may range from 0.1 mg to 1.0 mg. Adjust dosage upward or downward according to the patient's response.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Jun 25 22:22:19 UTC 2021
Edited
by admin
on Fri Jun 25 22:22:19 UTC 2021
Record UNII
GWN3C4FTI8
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
RESERPINE HYDROCHLORIDE
WHO-DD  
Common Name English
RESERPINE HYDROCHLORIDE [WHO-DD]
Common Name English
YOHIMBAN-16-CARBOXYLIC ACID, 11,17-DIMETHOXY-18-((3,4,5-TRIMETHOXYBENZOYL)OXY)-, METHYL ESTER, MONOHYDROCHLORIDE, (3.BETA.,16.BETA.,17.ALPHA.,18.BETA.,20.ALPHA.)-
Systematic Name English
3.BETA.,20.ALPHA.-YOHIMBAN-16.BETA.-CARBOXYLIC ACID, 18.BETA.-HYDROXY-11,17.ALPHA.-DIMETHOXY-METHYL ESTER 3,4,5-TRIMETHOXYBENZOATE (ESTER), MONOHYDROCHLORIDE
Systematic Name English
Code System Code Type Description
ECHA (EC/EINECS)
241-074-6
Created by admin on Fri Jun 25 22:22:19 UTC 2021 , Edited by admin on Fri Jun 25 22:22:19 UTC 2021
PRIMARY
PUBCHEM
21155894
Created by admin on Fri Jun 25 22:22:19 UTC 2021 , Edited by admin on Fri Jun 25 22:22:19 UTC 2021
PRIMARY
FDA UNII
GWN3C4FTI8
Created by admin on Fri Jun 25 22:22:19 UTC 2021 , Edited by admin on Fri Jun 25 22:22:19 UTC 2021
PRIMARY
CAS
16994-56-2
Created by admin on Fri Jun 25 22:22:19 UTC 2021 , Edited by admin on Fri Jun 25 22:22:19 UTC 2021
PRIMARY
EVMPD
SUB04219MIG
Created by admin on Fri Jun 25 22:22:19 UTC 2021 , Edited by admin on Fri Jun 25 22:22:19 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY